Drug Discovery · Shanghai, China · Founded 2019 · Privately Held (backing)
Developer of small molecule cardiac myosin inhibitor drug treatments designed for the treatment of hypertrophic cardiomyopathy, in-licensed from Cytokinetics. CORXEL Pharmaceuticals is based in Shanghai, China and was founded in 2019. Its last reported valuation was $475 million in Sep 2024. It has raised $452 million across 1 recorded round; the latest was a $287 million Series D1 in Jan 2026.
Last reported valuation
$474.9M
Oct 2026
Priced at
—
Total raised
$451.8M
Last round
Later Stage VC (Series D1)
Jan 2026
No prints on record
No secondary trades in CORXEL Pharmaceuticals shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of CORXEL Pharmaceuticals with a free account
·The complete investor list: 13 names
·Watch CORXEL Pharmaceuticals: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of CORXEL Pharmaceuticals stock.
